Keyword: infliximab, sepsis, survival, multiple organ dysfunction, vascular reactivity and mesenteric arterial blood flow https://mc06.manuscriptcentral.com/cjpp-pubs Canadian Journal of Physiology and Pharmacology Abstract Tumor necrosis factor-alpha (TNF-α) is a pivotal mediator that triggers inflammatory process, oxidative stress and multiple organ injury in sepsis. We investigated the effects of infliximab on survival, mesenteric artery blood flow (MBF), vascular reactivity, oxidative and

more »

... flammatory injuries in cecal ligation and puncture (CLP) induced sepsis. Wistar rats were divided into Sham, CLP, Sham+infliximab, CLP+infliximab subgroups. 24 hours before the operations rats were injected intraperitoneally with infliximab (7 mg/kg) or vehicle (saline; 1 mL/kg). 20 hours after operations MBF and phenylephrine responses of isolated aortic rings were measured. Tissue damages were examined biochemically and histopathologically. Furthermore, survival rates were monitored throughout 96 hours. Infliximab improved survival, mesenteric perfusion and aortic function after CLP. Increases of serum AST, ALT, LDH, BUN, Cr and inflammatory cytokines (tumor necrosis factor-alpha, interleukin-1 beta and interleukin-6) induced by CLP were blocked by infliximab. Infliximab prevented malondialdehyde elevations in septic liver, lung, spleen and kidney tissues and as well as glutathione reductions in septic liver, spleen and kidney tissues. Protective effects of infliximab on multiple organ damage were also observed histopathologically. Infliximab showed protective effects in sepsis due to its improvement effects on mesenteric perfusion, aortic function and its anti-inflammatory and antioxidative effects.